Hypothesis

Oral emodin reaches the lumen at high concentration, where it inhibits NLRP3 inflammasome activation in intestinal macrophages and epithelial cells, thereby reducing microbiome‑triggered IL‑1β release and preserving barrier integrity. This local senomorphic shift dampens the systemic inflammasome cascade that drives microglial priming in the aged brain, producing a gut‑brain anti‑aging effect independent of systemic drug exposure.

Mechanistic model

1. Microbiome‑derived danger signals – Age‑associated dysbiosis increases circulating LPS and microbial DNA, activating TLR4/NLRP3 in gut‑resident immune cells (1).
2. Emodin’s intestinal action – By binding the NLRP3 NACHT domain (as shown in LPS‑shock models)[1], emodin blocks caspase‑1 cleavage and IL‑1β maturation in the lamina propria.
3. Barrier protection – Reduced inflammasome activity limits oxidative tight‑junction damage, maintaining claudin‑1 and occludin expression, which prevents endotoxin translocation (5).
4. Systemic spill‑over – Lower portal‑veil IL‑1β decreases hepatic acute‑phase response and reduces circulating inflammasome complexes that would otherwise prime cerebral microglia via the vagus nerve or humoral routes.
5. Feedback to microbiome – A less inflamed mucosa favors growth of short‑chain‑fatty‑acid producers, further suppressing NLRP3 via HDAC inhibition, creating a virtuous loop.

Testable predictions

• Prediction 1: In aged mice fed emodin (50 mg/kg/day) for 8 weeks, fecal IL‑1β and calprotectin will drop ≥30 % compared with vehicle, while plasma LPS‑binding protein will decline correspondingly.
• Prediction 2: 16S rRNA sequencing will reveal a ↑ relative abundance of butyrate‑generating taxa (e.g., Faecalibacterium, Roseburia) and a ↓ Enterobacteriaceae load, correlating with the IL‑1β reduction.
• Prediction 3: Brain homogenates from emodin‑treated mice will show decreased NLRP3, ASC speck formation, and Iba1‑positive microglial morphology indicative of a resting state, without detectable emodin in cerebrospinal fluid (<5 ng/mL).
• Prediction 4: Antibiotic depletion of the gut microbiota will abolish the neuroprotective effect of emodin, confirming microbiome dependence.
• Prediction 5: Fecal microbiota transplant from emodin‑treated donors into germ‑free aged recipients will recapitulate the reduction in hippocampal IL‑1β and improve performance in the Morris water maze, even in the absence of direct drug exposure.

Experimental outline

• Use 20‑month‑old C57BL/6 mice, split into vehicle, emodin low, emodin high, and emodin + broad‑spectrum antibiotics groups (n = 10 per group).
• Measure fecal cytokines, plasma LPS‑binding protein, 16S profiling, intestinal histology (zonula occludens‑1 staining), brain NLRP3 inflammasome readouts, and behavioral cognition.
• Include a sham‑transplant cohort to test causality of microbiota transfer.

If the predictions hold, emodin would be re‑positioned as a gut‑targeted senomorphic that interrupts the microbiome‑inflammasome‑brain axis, offering a mechanistic explanation for its observed peripheral anti‑inflammatory potency despite low systemic bioavailability.